Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature

Marco Bandini, A Smith, M Marchioni, RS Pompe, TF Martel, L Cindolo, F Montorsi, SF Shariat, A Briganti, A Kapoor, U Capitanio, PI Karakiewicz

Research output: Contribution to journalArticle

Abstract

To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer. The ClinicalTrials.gov website was queried to identify ongoing trials. Traditional adjuvant therapy agents consisted of interferon α, interleukin 2, autologous tumor cell vaccines, and monoclonal antibodies. None provided survival benefit. Three contemporary studies (S-TRAC, ASSURE, and PROTECT) using targeted therapy compared sunitinib to placebo (S-TRAC), sunitinib or sorafenib to placebo (ASSURE), and pazopanib to placebo (PROTECT), with controversial results. In contrast to ASSURE and PROTECT, S-TRAC demonstrated improved disease-free survival. Several trials that use checkpoint immunotherapy agents or vascular endothelial growth factor receptor tyrosine kinase inhibitors are ongoing. Many traditional therapies have shown no success as adjuvant therapy for nmRCC after nephrectomy. Targeted adjuvant therapy for nmRCC after nephrectomy showed controversial results, and its routine use is not currently endorsed. © 2018 Elsevier Inc.
Original languageEnglish
Pages (from-to)176-183
Number of pages8
JournalClinical Genitourinary Cancer
Volume16
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Renal Cell Carcinoma
Nephrectomy
Placebos
Therapeutics
Molecular Targeted Therapy
Cancer Vaccines
Vascular Endothelial Growth Factor Receptor
Kidney Neoplasms
PubMed
Protein-Tyrosine Kinases
Immunotherapy
Interferons
Libraries
Disease-Free Survival
Interleukin-2
Monoclonal Antibodies
Databases
Survival
Neoplasms

Cite this

Bandini, M., Smith, A., Marchioni, M., Pompe, RS., Martel, TF., Cindolo, L., ... Karakiewicz, PI. (2018). Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. Clinical Genitourinary Cancer, 16(3), 176-183. https://doi.org/10.1016/j.clgc.2018.01.003

Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. / Bandini, Marco; Smith, A; Marchioni, M; Pompe, RS; Martel, TF; Cindolo, L; Montorsi, F; Shariat, SF; Briganti, A; Kapoor, A; Capitanio, U; Karakiewicz, PI.

In: Clinical Genitourinary Cancer, Vol. 16, No. 3, 2018, p. 176-183.

Research output: Contribution to journalArticle

Bandini, M, Smith, A, Marchioni, M, Pompe, RS, Martel, TF, Cindolo, L, Montorsi, F, Shariat, SF, Briganti, A, Kapoor, A, Capitanio, U & Karakiewicz, PI 2018, 'Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature', Clinical Genitourinary Cancer, vol. 16, no. 3, pp. 176-183. https://doi.org/10.1016/j.clgc.2018.01.003
Bandini, Marco ; Smith, A ; Marchioni, M ; Pompe, RS ; Martel, TF ; Cindolo, L ; Montorsi, F ; Shariat, SF ; Briganti, A ; Kapoor, A ; Capitanio, U ; Karakiewicz, PI. / Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. In: Clinical Genitourinary Cancer. 2018 ; Vol. 16, No. 3. pp. 176-183.
@article{6f2fa86428754955ad6b184081f51675,
title = "Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature",
abstract = "To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer. The ClinicalTrials.gov website was queried to identify ongoing trials. Traditional adjuvant therapy agents consisted of interferon α, interleukin 2, autologous tumor cell vaccines, and monoclonal antibodies. None provided survival benefit. Three contemporary studies (S-TRAC, ASSURE, and PROTECT) using targeted therapy compared sunitinib to placebo (S-TRAC), sunitinib or sorafenib to placebo (ASSURE), and pazopanib to placebo (PROTECT), with controversial results. In contrast to ASSURE and PROTECT, S-TRAC demonstrated improved disease-free survival. Several trials that use checkpoint immunotherapy agents or vascular endothelial growth factor receptor tyrosine kinase inhibitors are ongoing. Many traditional therapies have shown no success as adjuvant therapy for nmRCC after nephrectomy. Targeted adjuvant therapy for nmRCC after nephrectomy showed controversial results, and its routine use is not currently endorsed. {\circledC} 2018 Elsevier Inc.",
author = "Marco Bandini and A Smith and M Marchioni and RS Pompe and TF Martel and L Cindolo and F Montorsi and SF Shariat and A Briganti and A Kapoor and U Capitanio and PI Karakiewicz",
year = "2018",
doi = "10.1016/j.clgc.2018.01.003",
language = "English",
volume = "16",
pages = "176--183",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature

AU - Bandini, Marco

AU - Smith, A

AU - Marchioni, M

AU - Pompe, RS

AU - Martel, TF

AU - Cindolo, L

AU - Montorsi, F

AU - Shariat, SF

AU - Briganti, A

AU - Kapoor, A

AU - Capitanio, U

AU - Karakiewicz, PI

PY - 2018

Y1 - 2018

N2 - To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer. The ClinicalTrials.gov website was queried to identify ongoing trials. Traditional adjuvant therapy agents consisted of interferon α, interleukin 2, autologous tumor cell vaccines, and monoclonal antibodies. None provided survival benefit. Three contemporary studies (S-TRAC, ASSURE, and PROTECT) using targeted therapy compared sunitinib to placebo (S-TRAC), sunitinib or sorafenib to placebo (ASSURE), and pazopanib to placebo (PROTECT), with controversial results. In contrast to ASSURE and PROTECT, S-TRAC demonstrated improved disease-free survival. Several trials that use checkpoint immunotherapy agents or vascular endothelial growth factor receptor tyrosine kinase inhibitors are ongoing. Many traditional therapies have shown no success as adjuvant therapy for nmRCC after nephrectomy. Targeted adjuvant therapy for nmRCC after nephrectomy showed controversial results, and its routine use is not currently endorsed. © 2018 Elsevier Inc.

AB - To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer. The ClinicalTrials.gov website was queried to identify ongoing trials. Traditional adjuvant therapy agents consisted of interferon α, interleukin 2, autologous tumor cell vaccines, and monoclonal antibodies. None provided survival benefit. Three contemporary studies (S-TRAC, ASSURE, and PROTECT) using targeted therapy compared sunitinib to placebo (S-TRAC), sunitinib or sorafenib to placebo (ASSURE), and pazopanib to placebo (PROTECT), with controversial results. In contrast to ASSURE and PROTECT, S-TRAC demonstrated improved disease-free survival. Several trials that use checkpoint immunotherapy agents or vascular endothelial growth factor receptor tyrosine kinase inhibitors are ongoing. Many traditional therapies have shown no success as adjuvant therapy for nmRCC after nephrectomy. Targeted adjuvant therapy for nmRCC after nephrectomy showed controversial results, and its routine use is not currently endorsed. © 2018 Elsevier Inc.

U2 - 10.1016/j.clgc.2018.01.003

DO - 10.1016/j.clgc.2018.01.003

M3 - Article

VL - 16

SP - 176

EP - 183

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

ER -